Abstract 13628: Cardiovascular Toxicity Associated With Vascular Endothelial Growth Factor Receptor Inhibitors Use in Oncology: A Network Meta-Analysis of Phase 3 Clinical Trials

Introduction: Which vascular endothelial growth factor receptor inhibitor (VEGFRi) is less cardiotoxic compared to others in same class is not well known. We compared cardiovascular safety profile ...